Sanifit Therapeutics S.a.

Laboratorios Sanifit, S.l.

Laboratoris Sanifit, S.l.

Carolina Salcedo Roca

Joan Perello Bestard

Bernat Isern Amengual

Miguel David Ferrer Reynes

Pieter H Joubert

Ana-Zeralda Canals Hamann

Miquel David Ferrer Reynes

The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.

IP and IP analogs dosage regimens for the treatment of ectopic calcifications

Use of a derivative containing C&#x2014;O&#x2014;P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.

Use of derivatives containing C-O-P bonds in patients with kidney failure

Use of a derivative containing C&#x2014;O&#x2014;P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimirnetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.

Use of derivatives containing C&#x2014;O&#x2014;P bonds in patients with kidney failure

Growing community of inventors

Palma De Mallorca, Spain

Carolina Salcedo Roca